Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (se deschide o fereastră nouă)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Sursă‎: Cancer 2013;119(21):3784-7.

Index‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (se deschide o fereastră nouă)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (se deschide o fereastră nouă)

Chakrabarti S, Varma S, Singh S, Kumari S

Sursă‎: Eur J Haematol 1998;60(5):313-4.

Index‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (se deschide o fereastră nouă)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (se deschide o fereastră nouă)

Delaney M, Matthews DC, Gernsheimer TB

Sursă‎: Pediatr Blood Cancer 2017;64(12):e26641.

Index‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (se deschide o fereastră nouă)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (se deschide o fereastră nouă)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Sursă‎: J Urol 2010;184(3):1152-7.

Index‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (se deschide o fereastră nouă)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (se deschide o fereastră nouă)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Sursă‎: Leuk Lymphoma 1995;19(1-2):141-4.

Index‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (se deschide o fereastră nouă)

Pediatric off-label use of recombinant factor VIIa. (se deschide o fereastră nouă)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Sursă‎: Pediatrics 2009;123(3):1066-72.

Index‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (se deschide o fereastră nouă)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (se deschide o fereastră nouă)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Sursă‎: Indian J Pediatr 2011;78(8):961-8.

Index‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (se deschide o fereastră nouă)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (se deschide o fereastră nouă)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Sursă‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Index‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (se deschide o fereastră nouă)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (se deschide o fereastră nouă)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Sursă‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Index‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (se deschide o fereastră nouă)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (se deschide o fereastră nouă)

Das P, Carcao M, Hitzler J

Sursă‎: Pediatr Blood Cancer 2006;47(2):206-9.

Index‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (se deschide o fereastră nouă)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (se deschide o fereastră nouă)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Sursă‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Index‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (se deschide o fereastră nouă)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (se deschide o fereastră nouă)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Sursă‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Index‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (se deschide o fereastră nouă)

Off-label use of recombinant factor VIIa in pediatric patients. (se deschide o fereastră nouă)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Sursă‎: Pediatrics 2012;129(6):e1533-40.

Index‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (se deschide o fereastră nouă)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (se deschide o fereastră nouă)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Sursă‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Index‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (se deschide o fereastră nouă)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (se deschide o fereastră nouă)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Sursă‎: Med Oncol 2010;27(1):16-9.

Index‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (se deschide o fereastră nouă)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (se deschide o fereastră nouă)

Ucar C, Caliskan U

Sursă‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Index‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (se deschide o fereastră nouă)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (se deschide o fereastră nouă)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Sursă‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Index‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (se deschide o fereastră nouă)

The use of DDAVP in children with bleeding disorders. (se deschide o fereastră nouă)

Ben-Ami T, Revel-Vilk S

Sursă‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Index‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (se deschide o fereastră nouă)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (se deschide o fereastră nouă)

Kobrinsky NL, Tulloch H

Sursă‎: J Pediatr 1988;112(6):993-6.

Index‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (se deschide o fereastră nouă)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (se deschide o fereastră nouă)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Sursă‎: J Pediatr Surg 2013;48(3):689-94.

Index‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (se deschide o fereastră nouă)